BioNTech
initial results in dose show a manageable safety profile with most aes being grade or protein therapeutics | BioNTech
Company
Deck Type
Sector
Industry
Deck date
June 2022
Slide
118 of 156
Related slides by other companies
Genprex
Investor Presentation
November 2024
phase dose in relapsed patients | Genprex
Alkermes
Results
June 2021
artistry phase efficacy expansion initiated following determination of subcutaneous | Alkermes
BioAtla
Investor Presentation
January 2024
cab phase dose titration ongoing | BioAtla
Nuvalent
Investor Presentation
February 2024
preliminary safety profile favorable and consistent with alk selective sparing design of phase treatment related adverse events in patients all treated patients has not been identified transient asymptomatic grade increase infrequent requiring dose modification discontinued due to dose reduced due to overall avoiding related any alt increased ast increased nausea constipation fatigue peripheral edema grade grade grade any grade resulting in treat resulting in dose reduced dose for source lin grade alt ast elevation grade nausea cognitive disturbance grade elevation grade treatment continues at the city treatment related adverse event at from | Nuvalent
Other recent decks by BioNTech
See all presentations (12 decks)
Investor Presentation
August 2022
Results
August 2022
Results
March 2022
Investor Day
February 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io